Gastrointestinal Gastroesophageal cancer

Adenocarcinoma

Newly diagnosed, locoregional
Locally advanced, non-surgery candidate
Oligometastatic, HER2 negative
No T4b, no metastatic disease

Adenocarcinoma or Squamous cell carcinoma

Metastatic or locally advanced

S1922

Adeno-carcinoma of the small intestine

Deficient DNA Mismatch Repair, Stage III
Newly diagnosed, Post-resection, Stage IIA

HER-2 Amplification Adenocarcinoma

S1613

Adeno-carcinoma of the colon

Deficient DNA Mismatch Repair, Stage IV

No dMMR or MSI-H disease, Advanced/Metastatic

Stage II-III Low rectum, high risk
Stage T1-2N0M0, Tumor <=4cm
Stage II (T3N0 only), IIIA or IIIB

NRG-GI005 (COBRA)

NRG-GI004 (COMMIT)

NRG-GI002 (TNT)

EA2182 (DECREASE)

EA2165

Adeno-carcinoma of the rectum

Stage II (T3N0 only), IIIA or IIIB

EA2186 (GIAN T)

Newly diagnosed, resectable, Tx-4, N0-1, M0

A021806

Anal cancer

Stage II (T3N0 only), IIIA or IIIB

EA2182 (DECREASE)

EA2165

Metastatic, untreated (Elderly patients)

Newly diagnosed, resectable, Tx-4, N0-1, M0

EA2186 (GIAN T)

Newly diagnosed, resectable, Tx-4, N0-1, M0

A021806

Metastatic or Unresectable

S1815

EA2187

Proton vs. Photon
Sorafenib with vs. without SBRT

NRG-GI003

RTOG-1112

Billiary tract cancers

Metastatic or Unresectable

S1815

EA2187

Hepatocellular carcinoma

Newly diagnosed

Progressed

NRG-GI003

RTOG-1112

NCTN Gastrointestinal Cancer Trials Portfolio (Open as of 8/17/2020)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.
Cross-disease trials:

- EAY131 (MATCH)
- S1609 (DART)
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Phase</th>
<th>Protocol Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>A021502</td>
<td>III</td>
<td>Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair</td>
</tr>
<tr>
<td>A021602</td>
<td>III</td>
<td>Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced NEuroendocrine Tumors After Progression on Everolimus (CABINET)</td>
</tr>
<tr>
<td>A021703</td>
<td>III</td>
<td>Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)</td>
</tr>
<tr>
<td>A021806</td>
<td>III</td>
<td>A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer</td>
</tr>
<tr>
<td>EA2142</td>
<td>II</td>
<td>Randomized Phase II Study of Platinum and Etoposide Versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas</td>
</tr>
<tr>
<td>EA2165</td>
<td>II</td>
<td>A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer</td>
</tr>
<tr>
<td>EA2174</td>
<td>II/III</td>
<td>A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma</td>
</tr>
<tr>
<td>EA2182</td>
<td>II</td>
<td>A Randomized Phase II Study of De-Extensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)</td>
</tr>
<tr>
<td>EA2183</td>
<td>III</td>
<td>A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)</td>
</tr>
<tr>
<td>EA2186</td>
<td>II</td>
<td>A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)</td>
</tr>
<tr>
<td>EA2187</td>
<td>II</td>
<td>A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma</td>
</tr>
<tr>
<td>NRG-G1002</td>
<td>II</td>
<td>A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer</td>
</tr>
<tr>
<td>NRG-G1003</td>
<td>III</td>
<td>A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma</td>
</tr>
<tr>
<td>NRG-G1004</td>
<td>III</td>
<td>Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer</td>
</tr>
<tr>
<td>NRG-G1005</td>
<td>II/III</td>
<td>Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)</td>
</tr>
<tr>
<td>NRG-G1006</td>
<td>III</td>
<td>Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer</td>
</tr>
<tr>
<td>NRG-G1007</td>
<td>I</td>
<td>Phase I Trial with Expansion Cohort of OBP-301 (Telomelysin) and Definitive Chemoradiation for Patients with Locally Advanced Esophageal and Gastric Adenocarcinoma Who Are Not Candidates for Surgery</td>
</tr>
<tr>
<td>RTOG-1112</td>
<td>III</td>
<td>Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma</td>
</tr>
<tr>
<td>S1613</td>
<td>II</td>
<td>A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification</td>
</tr>
<tr>
<td>S1815</td>
<td>III</td>
<td>A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers</td>
</tr>
<tr>
<td>S1922</td>
<td>II</td>
<td>Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma</td>
</tr>
<tr>
<td>EAY131</td>
<td>II</td>
<td>Molecular Analysis for Therapy Choice (MATCH)</td>
</tr>
<tr>
<td>S1609</td>
<td>II</td>
<td>DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors</td>
</tr>
</tbody>
</table>

This portfolio shows NCTN trials. For information about NCORP trials, please see: [https://ncorp.cancer.gov/find-a-study/](https://ncorp.cancer.gov/find-a-study/)